openPR Logo
Press release

What Are Components And Mechanism Action of Antibody-Drug Conjugates

What Are Components And Mechanism Action of Antibody-Drug

Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell.

Compared to alternative cancer treatments, for example, chemotherapy, immunotherapy, radiation, and stem cell therapy, ADC combines chemotherapy and immunotherapy and allows selective delivery of anticancer drugs and reduces systemic exposure and toxicity of anticancer drugs.

Components of ADC

One of the key requirements of ADC is the ability of monoclonal antibodies (mAb) to recognize tumor markers. These are unique antigenic markers highly expressed on cancer cells but are not found or in a low level of expression on normal, healthy cells.

For example, the HER2 (human epidermal growth receptor 2) receptor is expressed in cancer cells 100-fold higher than normal cells.  Moreover, the markers should possess internalization properties that allow the ADC to be transported into the cancer cell upon binding. This enhances the ability of the drug to perform cancer-killing activities.

The mAb component of ADC is important and should fulfill several requirements: it should have high specificity and binding affinity to the target tumor marker. This ensures the mAb only targets cancer cells. The mAb should also have low immunogenicity and no cross-reactivity. In the first and second generation of ADCs, the mAb is a chimera of human and mouse antibodies.

Despite its high efficacy, it sometimes generated an immune response in the human body against the mouse component of the antibody. Because of this, third-generation ADC employs fully human antibodies, and these are used to treat cancers such as HER-2–positive metastatic breast cancer.

The cytotoxic payloads are another important component of ADC: it is the cancer cell-killing drug that is linked to the mAb. The cytotoxic payload is stable and non-toxic when linked to the ADC and is activated once cleaved from the ADC inside the cytoplasm of cancer cells. There are 2 main drug classes used in ADC: microtubule-disrupting agents and DNA-damaging agents.

Mechanism of action

ADC is administrated intravenously into the bloodstream to avoid linker cleavage by acid and enzymes in the digestive system. Upon recognition of the mAb component to tumor-specific markers, ADC is internalized into cancer cells via receptor-mediated endocytosis.

Environmental changes such as low pH in the endosome and the presence of lysosomes inside the cell trigger the release of the cytotoxic payload of ADC. When released, the cytotoxic payload interferes with cellular mechanisms and induce programmed cell death – apoptosis.

Resistance to ADC

Although ADC provides a highly specific, low immunogenic cancer therapy, cancer cells that are pressured to survive ADC treatment lead to resistance to ADC. Resistance can be acquired, or cancer cells can be intrinsically resistant to different components of the ADC.

Tumour marker-related resistance can be due to decreased expression levels of the markers or masking of the marker with the extracellular matrix. Also, the upregulation of drug efflux pumps can expel cytotoxic payload from the cytoplasm of cancer cells. This limits the clinical success of ADC.

Future perspectives

As one of the research and development hotspots in the field of medicine, more than 100 ADCs are currently in different stages of clinical development, and there are hundreds of ongoing clinical trials.

To date, a total of twelve ADCs have been approved by the FDA, including: Kadcyla, Adcetris, Besponsa, Mylotarg, Lumoxiti, Polivy,Padcev, Trodelvy, Enhertu, Blenrep , ZYNLONTA, and Tivdak.

All in all, ADC is a promising therapeutic approach to treating cancers and is being constantly improved and developed.

Biopharma PEG, as a professional PEG derivatives supplier, is dedicated to being your most reliable partner to provide chemical synthesis and high-quality PEG linkers. We are committed to promoting the progress of yourADC discovery and development projects.

Biopharma PEG Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
TEL: 1-857-366-6766
Fax: 617-206-9595

Biochempeg is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and reagents, monodisperse PEG, Click Chemistry reagents,  PEGylation services and  custom PEG derivative synthesis to clients worldwide. These PEG reagents have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery and diagnostics field. 

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release What Are Components And Mechanism Action of Antibody-Drug Conjugates here

News-ID: 2509830 • Views:

More Releases from Biochempeg Scientific Inc.

Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,
Semaglutide VS Liraglutide: Which Is Better For Weight Loss
Semaglutide VS Liraglutide: Which Is Better For Weight Loss
Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association. Domenica M. Rubino, M.D., from the Washington Center for Weight Management and Research in Arlington, Virginia, and colleagues compared the efficacy and adverse event
Sacituzumab govitecan shows promise in treating the most aggressive type of breast cancer
Sacituzumab govitecan shows promise in treating the most aggressive type of brea …
A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as
ADC Has Curative Effect On Cell Surface Protein In Neuroblastoma
ADC Has Curative Effect On Cell Surface Protein In Neuroblastoma
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells. The researchers published their findings today in Science Translational Medicine. In 2008, researchers discovered mutations in the anaplastic lymphoma kinase (ALK) gene as the major cause of the inherited form of neuroblastoma and showed that these same mutations

All 5 Releases

More Releases for ADC

Latest Azodicarbonamide (ADC) Market 2022 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Azodicarbonamide (ADC) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Azodicarbonamide (ADC) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Azodicarbonamide (ADC) report includes a professional in-depth study
Global ADC Blowing Agents Market Analysis by 2020-2025
Global Info Research offers a latest published report on ADC Blowing Agents Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global ADC Blowing Agents Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure
ADC Blowing Agents Market Demand by 2025: QY Research
Global ADC Blowing Agents market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail information about
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends. This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering National Semiconductor Nippon Precision Circuits Inc Micro Analog systems Microchip Technology. TelCom Semiconductor, Inc Vishay Siliconix Texas
SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London
Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75